Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure

by Weerawat Manosuthi, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy

by Somnuek Sungkanuparph, Boonchuay Eampokalap, Suthat Chottanapund, Supeda Thongyen, Weerawat Manosuthi
Published 2018

Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy

by Weerawat Manosuthi, Suthat Chottanapand, Supeda Thongyen, Achara Chaovavanich, Somnuek Sungkanuparph
Published 2018

HIV-1 drug resistance-associated mutations among antiretroviral-naive thai patients with chronic HIV-1 infection

by Weerawat Manosuthi, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Single-boosted protease inhibitor versus double-boosted protease inhibitors for the salvage therapy in HIV-infected patients

by Weerawat Manosuthi, Sukanya Chimsuntorn, Supeda Thongyen, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen

by Weerawat Manosuthi, Chonlaphat Sukasem, Supeda Thongyen, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Comparison of thai government manufactured tenofovir (Tenofovir GPO300) with privately manufactured tenofovir (Viread) used along with lamivudine and efavirenz to treat Thai HIV pa...

by Weerawat Manosuthi, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection

by Dunyaporn Trachootham, Supeda Thongyen, Aroonwan Lam-Ubol, Nattida Chotechuang, Wannarat Pongpirul, Wisit Prasithsirikul
Published 2022

Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: A four-year prospective study

by Weerawat Manosuthi, Preecha Tantanathip, Sukanya Chimsuntorn, Boonchuay Eampokarap, Supeda Thongyen, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazo...

by Weerawat Manosuthi, Somnuek Sungkanuparph, Supeda Thongyen, Nopphanath Chumpathat, Boonchuay Eampokalap, Unchana Thawornwan, Suporn Foongladda
Published 2018

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure

by Weerawat Manosuthi, Sasisopin Kiertiburanakul, Wannarat Amornnimit, Wisit Prasithsirikul, Supeda Thongyen, Samruay Nilkamhang, Kiat Ruxrungtham, Somnuek Sungkanuparph
Published 2018

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy

by Weerawat Manosuthi, Chonlaphat Sukasem, Aroon Lueangniyomkul, Wiroj Mankatitham, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

by Weerawat Manosuthi, Chonlaphat Sukasem, Aroon Lueangniyomkul, Wiroj Mankatitham, Supeda Thongyen, Samruay Nilkamhang, Sukanya Manosuthi, Somnuek Sungkanuparph
Published 2018

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study

by Weerawat Manosuthi, Aroon Lueangniyomkul, Wiroj Mankatitham, Sukanya Chimsuntorn, Preecha Tantanathip, Supeda Thongyen, Busakorn Suntisuklappon, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study

by Weerawat Manosuthi, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Sirirat Likanonsakul, Pawita Suwanvattana, Unchana Thawornwan, Busakorn Suntisuklappon, Samruay Nilkamhang, Somnuek Sungkanuparph
Published 2018

Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifa...

by Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Boonchuay Eampokarap, Sumonmal Uttayamakul, Pawita Suwanvattana, Samroui Kaewsaard, Kiat Ruxrungtham
Published 2018

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in hiv-infected patients receiving rif...

by Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Aroon Lueangniyomkul, Wiroj Mankatitham, Wisit Prasithsirskul, Sunantha Burapatarawong, Supeda Thongyen, Sirirat Likanonsakul, Unchana Thawornwa, Vilaiwan Prommool, Kiat Ruxrungtham
Published 2018